Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | CASP6 | P55212 | 1/20 | 0.53 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2946066 | 0.89 | ALDH1A1 (0.74) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL32660003 | 0.87 | L3MBTL1 (0.70) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL16982337 | 0.87 | MEN1 (0.68) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL30309467 | 0.87 | L3MBTL1 (0.58) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL17747815 | 0.86 | SMN1; SMN2 (0.61) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL520107 | 0.85 | SIRT6 (0.61) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL16982499 | 0.85 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL27785049 | 0.85 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1GAAKDM4EMEN1 | |
| SCHEMBL520898 | 0.85 | ALDH1A1 (0.66) | L3MBTL1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL10240070 | 0.85 | SMN1; SMN2 (0.63) | L3MBTL1ALDH1A1GAAKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116217551-B | Substituted indazole or azaindazole compounds and application thereof | 河南中医药大学 | 2024-07-30 | — | — | CN | disclosed |
| CN-113214287-B | HPK1 inhibitors and methods of use thereof | 大学健康网络 | 2023-10-20 | — | — | CN | disclosed |
| CN-112047932-B | Pyrazole spleen tyrosine kinase inhibitor and preparation method and application thereof | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIVERSITY HEALTH NETWORK (CA) | 2022-01-06 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059832-B2 | HPK1 inhibitors and methods of using same | UNIVERSITY HEALTH NETWORK (CA) | 2021-07-13 | — | — | US | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| EP-3322711-B1 | HPK1 INHIBITORS AND METHODS OF USING SAME | UNIV HEALTH NETWORK (CA) | 2021-03-10 | — | — | EP | disclosed |
| EP-3186247-B1 | PROTEIN KINASE INHIBITORS | ASTAR BIOTECH LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-2395000-A1 | Benzimidazole compounds that modulate the activity of CDK, GSK and aurora kinases | Astex Therapeutics Limited (GB) | 2011-12-14 | — | — | EP | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| US-20100004232-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (UK) | 2010-01-07 | — | — | US | disclosed |
| EP-1968579-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2008-09-17 | — | — | EP | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | ASTEX THERAPEUTICS LIMITED (GB) | 2008-06-05 | — | — | US | disclosed |
| EP-1833819-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | Astex Therapeutics Limited (GB) | 2007-09-19 | — | — | EP | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2007077435-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006070195-A1 | PYRAZOLE COMPOUNDS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059832-B2 | HPK1 inhibitors and methods of using same | PDXK, PDK3, PDK2 | L3MBTL1 3378/4885ALDH1A1 2442/4885GAA 3453/4885 |
| US-20100004232-A1 | Pharmaceutical Compounds | ERBB3, ABL1, RET | L3MBTL1 1345/4885ALDH1A1 3042/4885GAA 3397/4885 |
| US-20220002313-A1 | HPK1 INHIBITORS AND METHODS OF USING SAME | PDXK, PDK3, PDK2 | L3MBTL1 3317/4885ALDH1A1 2458/4885GAA 3500/4885 |
| US-20080132495-A1 | Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases | CDK3, CDK1, AURKA | L3MBTL1 2376/4885ALDH1A1 3717/4885GAA 3595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.